Company intelligence / Profile preview
Vivacelle Bio
Kansas City, Missouri, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 3
01
Overview
Vivacelle Bio’s lead asset, VBI-S, has entered a Phase 3 trial targeting patients with hypovolemia due to septic shock who have failed standard therapies. The product demonstrated strong efficacy in a Phase II trial—100% of treated patients achieved elevated blood pressure and improved organ function when refractory to standard care. The company’s technology addresses both absolute and relative hypovolemia by restoring intravascular volume and redistributing nitric oxide. Preclinical data for the earlier-stage product, VBI‑1, suggest it may be two-to-three times more effective than current standards in animal models.
- Therapeutic areas
- CardiovascularInfectious Diseases
- Modalities
- Phospholipid nanoparticles (novel resuscitation fluids)Small molecule drugs (as per pipeline classification)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
U.S. Department of Defense/Naval Medical Research Command via MTEC funding for clinical trialsNational Institutes of Health support
Beyond the preview
Go deeper on Vivacelle Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivacelle Bio.